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Abstract
Introduction Prostaglandins are integral components in the
cellular response to inflammation, promoting cellular
proliferation and angiogenesis. The enzyme responsible for the
conversion of arachidonic acid to prostaglandins in response to
inflammation is prostaglandin endoperoxide synthase 2/cyclo-
oxygenase 2 (PTGS2/COX2). Polymorphisms in the PTGS2
gene have been associated with various diseases, including
inflammatory bowel disease and cancer of the lung, colorectum,
and breast.
Methods We genotyped the five most common polymorphisms
(rs20417, rs5277, rs20432, rs5275, and rs4648298) in the
Nurses' Health Study (1,270 cases, 1,762 controls) to test the
hypothesis that polymorphisms in PTGS2 are associated with
breast cancer risk, using logistic regression analyses. The
Nurses' Health Study 2 (317 cases, 634 controls) and Harvard
Women's Health Study (702 cases, 703 controls) were used to
further examine putative associations.
Results The rs5275 polymorphism in the 3' untranslated region
of the PTGS2 gene was associated with a decrease in breast
cancer risk. We therefore genotyped this single-nucleotide
polymorphism in the Nurses' Health Study 2 and Harvard
Women's Health Study. Similar results were observed in these
subsequent analyses, with no statistically significant
heterogeneity in risk estimates between studies. In pooled
analyses, women homozygous for the T allele at rs5275 had a
20% lower risk of breast cancer than those homozygous for the
C allele (odds ratio 0.80, 95% confidence interval 0.66 to 0.97).
Conclusion Although this polymorphism may be associated
with a decrease in breast cancer risk among Caucasian women,
we provide strong evidence that it is not associated with an
increased risk of breast cancer.
Introduction
Inflammation is thought to have a role in many diseases, includ-
ing cancers [1]. Cellular response to inflammation signaling
can lead to increased expression of growth factors and their
receptors, which in turn can lead to cellular proliferation [2]. In
addition, by-products of the inflammatory response, such as
free radicals, can cause DNA damage [3-5]. Taken together,
these factors suggest a strong a priori hypothesis that inflam-
mation is related to the etiology of cancer.
Although there is an inflammatory type of breast cancer, this
accounts for only 1 to 5% of the overall incidence of breast
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cancer in the United States [6]. Non-steroidal anti-inflamma-
tory drugs have been shown to be inversely associated with
risk of colorectal cancer risk [7]. However, the association
between these drugs and breast cancer risk is unclear [8,9].
Nevertheless, causal relationships between prostaglandin
endoperoxide synthase 2/cyclo-oxygenase 2 (PTGS2/COX2)
and mammary epithelial tumorigenesis have been detected in
animal models [10].
PTGS2 is a protein that is expressed as part of the acute
response to inflammation [11] and is the main enzyme respon-
sible for transforming arachidonic acid into prostaglandins.
Prostaglandins in turn stimulate cell proliferation and angio-
genesis. Expression of PTGS2 is tightly controlled, with basal
levels low to nonexistent in most tissue types. In addition,
PTGS2  mRNA has a very short half-life regulated by
sequence-specific elements in the 3' untranslated region
(UTR) of the gene [12,13].
We hypothesize that polymorphisms in this gene could influ-
ence the risk of breast cancer, through altering the levels of
expression or activity of the PTGS2 enzyme. We have there-
fore genotyped five single-nucleotide polymorphisms (SNPs)
in the PTGS2 gene in the breast cancer cases and controls
nested within the Nurses' Health Study (NHS). One of these
polymorphisms was statistically associated with decreased
breast cancer risk, and we therefore sought to confirm this
association in the breast cancer cases and controls nested
within the Nurses' Health Study 2 (NHS2) and Harvard
Women's Health Study (WHS).
Materials and methods
The NHS nested breast cancer case-control study (cases, n =
1,270; controls, n = 1,762) is derived from 32,826 women
who were free of diagnosed breast cancer at blood collection
in 1989 and 1990, since when they were followed for incident
disease until 31 May 2000. Medical records were used to con-
firm the diagnoses in women who reported a diagnosis of
breast cancer on the biennial questionnaires. Control subjects
were matched to cases on the basis of age, menopausal sta-
tus, recent hormone replacement therapy, and blood-draw
specific variables (such as date and time of day). The NHS2
breast cancer case-control study (cases, n = 317; controls, n
= 634) is nested in a study of 29,611 women who were free
of diagnosed breast cancer at the time of blood draw
(between 1996 and 1999) and were followed for incident dis-
ease until 1 June 2003. The nested breast cancer case-control
study in the WHS began in 1993, when 28,263 women pro-
vided blood samples and were followed for incident disease
until 7 March 2000, with 702 cases and 703 controls. Cases
and controls were selected for the NHS2 and WHS with the
use of the same criteria as in the NHS. All three cohorts use
similar questionnaires to collect covariate information, admin-
istered biennially. Detailed descriptions of these three cohorts
have been published previously [14-16]. Informed consent
was obtained from all participants, and the study was
approved by the Institutional Review Board of the Brigham and
Women's Hospital.
PTGS2 is a very small gene (less than 10 kilobase pairs from
5' UTR to 3' UTR), with only five known common polymor-
phisms; linkage disequilibrium between them is high
(rs20417, rs5277, rs20432, rs5275, rs4648298 [17,18]; see
Table 1 for more information). These five SNPs were geno-
typed by means of the 5' nuclease assay (TaqMan; Applied
Biosystems, Foster City, CA, USA). The SNPs are located at
base pairs 926, 3,050, 5,209, 8,473, and 9,850 on GenBank
sequence D28235. rs20417 is in the 5' region, rs5277 is a
synonymous polymorphism in exon 3, rs20432 is in the intron
between exons 5 and 6, and both rs5275 and rs4648298 are
in the 3' UTR of PTGS2. TaqMan primers, probes, and condi-
tions for genotyping assays are available from the authors on
request. All genotyping was done with laboratory personnel
blinded to the case-control status of the samples and included
quality-control samples (DNA from cohort participants, not
part of the case-control study, repeated from 2 to 18 times
across plates) for validation. Concordance for quality-control
samples was 100%.
Statistical analysis was performed with SAS version 9.1 (SAS
Table 1
Pairwise linkage disequilibrium between SNPs selected for study in PTGS2
SNP PTGS2_20417 PTGS2_5277 PTGS2_5209 PTGS2_5275 PTGS2_4648298
PTGS2_20417 - 1 0.97 0.95 0.98
PTGS2_5277 0.03 - 1 1 0.84
PTGS2_5209 0.13 0.03 - 1 1
PTGS2_5275 0.1 0.06 0.11 - 1
PTGS2_4648298 0.01 0.002 0.02 0.01 -
Numbers above the diagonal are the Lewontin's D', a measure of linkage disequilibrium; numbers under the diagonal are the correlation coefficient 
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Institute, Cary, NC, USA). Haplotype estimation was per-
formed with PROC HAPLOTYPE, tests for deviation from
Hardy–Weinberg equilibrium were performed with PROC
ALLELE, and haplotype-specific odds ratios and 95% confi-
dence intervals were calculated with unconditional logistic
regression with PROC LOGISTIC, controlling for age (at
blood draw as a continuous variable), age at first birth (AFB),
parity (nulliparous; one or two children and AFB 24 years or
less; one or two children and AFB more than 24 years; more
than two children and AFB 24 years or less; more than two
children and AFB more than 24 years), menopausal status at
diagnosis (premenopausal, postmenopausal, unknown), his-
tory of benign breast disease (yes/no), and family history of
breast cancer (yes/no). Variables such as AFB, history of
benign breast disease, or family history of breast cancer are
updated in each questionnaire cycle, and the variable closest
to the diagnosis (cases) or index date (controls) is used in
these analyses. Cis-interactions, comparing associations with
haplotypes to those observed with independent SNPs, were
tested by comparing the model with the SNP genotype alone
to the model with each haplotype carrying the risk allele by
means of likelihood ratio testing. Interaction p values were cal-
culated by likelihood ratio testing, comparing the model with
main effects for each exposure (polymorphism and anti-inflam-
matory use) to the model including the cross-tabulation of the
two exposures. Heterogeneity between cohorts was calcu-
lated with Cochran-Mantel-Haenszel statistics in PROC
FREQ.
Results
We did not detect any deviation from Hardy–Weinberg equi-
librium among the controls in the NHS at any of the polymor-
phisms studied (data not shown). Only the rs5275
polymorphism in the 3' UTR of the PTGS2 gene showed an
association with risk of breast cancer (Table 2) and was there-
fore subsequently genotyped in the NHS2 and WHS. There is
almost complete linkage disequilibrium (Lewontin D' = 0.95)
between the rs20417 polymorphism 5' of PTGS2 and rs5275
3' of PTGS2. Similarly, one PTGS2 haplotype carrying the var-
iant allele of rs5275 was associated with a decrease in breast
cancer risk. However, the global test for difference in haplo-
type frequencies between breast cancer cases and controls
was not significant (p = 0.15; Table 3). Testing for cis-interac-
Table 2
Association between PTGS2 genotypes and breast cancer risk in the Nurses' Health Study
SNP Genotype Cases (percentage) Controls (percentage) OR (95% CI)a
PTGS2_20417 G/G 865 (69.6) 1,185 (69.1) 1.00 (reference)
G/C 336 (27.0) 485 (28.3) 0.93 (0.78–1.10)
C/C 42 (3.4) 45 (2.6) 1.28 (0.82–2.02)
p trend = 0.94
PTGS2_5277 G/G 875 (71.0) 1,217 (71.0) 1.00 (reference)
G/C 322 (26.1) 464 (27.1) 1.00 (0.84–1.19)
C/C 35 (2.8) 34 (2.0) 1.35 (0.81–2.26)
p trend = 0.55
PTGS2_5209 T/T 834 (69.4) 1,171 (69.5) 1.00 (reference)
T/G 330 (27.5) 472 (28.0) 0.97 (0.82–1.16)
G/G 38 (3.2) 43 (2.6) 1.24 (0.77–2.00)
p trend = 0.81
PTGS2_5275 T/T 541 (43.3) 699 (40.6) 1.00 (reference)
T/C 567 (45.4) 808 (47.0) 0.88 (0.75–1.04)
C/C 141 (11.3) 213 (12.4) 0.80 (0.62–1.03)
p trend = 0.05
PTGS2_4648298 A/A 1,180 (95.4) 1,654 (96.3) 1.00 (reference)
A/G + G/G 57 (4.6) 63 (3.7) 1.29 (0.88–1.88)
aUnconditional logistic regression controlled for age, BMI at age 18 years, menopausal status at diagnosis, history of benign breast disease, and 
family history of breast cancer. CI, confidence interval; PTGS2, prostaglandin endoperoxide synthase 2; OR, odds ratio; SNP, single-nucleotide 
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tion confirmed that this haplotype was not more strongly asso-
ciated with breast cancer risk than the rs5275 polymorphism
alone. No difference in genotype distribution of rs5275 was
observed between tumors positive or negative for sex steroid
hormone receptors, no significant difference in risk was
observed upon stratification by menopausal status, and no sta-
tistically significant interactions were detected between this
polymorphism and use of aspirin or other non-steroidal anti-
inflammatory drugs at baseline (evaluated only in the NHS;
data not shown).
Similar genotype distributions were observed among both the
NHS2 and WHS with respect to the NHS1 at rs5275. On
pooling the three data sets (Table 4), no heterogeneity among
the studies was detected (p = 0.12), and the pooled risk esti-
mate shows a moderately statistically significant trend of
decreasing risk with each variant rs5275 allele (odds ratio
0.91, 95% confidence interval 0.83 to 0.99, p = 0.02).
Table 3
PTGS2 haplotypes and breast cancer risk in the Nurses' Health Study
Haplotype Cases (percentage) Controls (percentage) OR (95% CI)a
z1 G-G-T-T-A 1,250 (49.4) 1,691 (48.2) 1.00 (reference)
z2 G-G-T-C-A 435 (17.2) 667 (19.0) 0.84 (0.72–0.98)
z3 G-C-T-T-A 403 (15.9) 544 (15.5) 0.99 (0.85–1.17)
z4 C-G-G-C-A 358 (14.1) 507 (14.5) 0.92 (0.79–1.09)
z5 C-G-G-C-G 53 (2.1) 63 (1.8) 1.16 (0.78–1.72)
Global p = 0.15
aUnconditional logistic regression controlled for age, BMI at age 18 years, menopausal status at diagnosis, history of benign breast disease, and 
family history of breast cancer. CI, confidence interval; OR, odds ratio; PTGS2, prostaglandin endoperoxide synthase 2.
Table 4
PTGS2 rs5275 genotype and breast cancer risk within the NHS1, NHS2, WHS, and pooled data
Study Genotype Cases (percentage) Controls (percentage) OR (95% CI)a
NHS1 T/T 541 (43.3) 699 (40.6) 1.00 (reference)
T/C 567 (45.4) 808 (47.0) 0.89 (0.75–1.04)
C/C 141 (11.3) 213 (12.4) 0.80 (0.62–1.03)
p trend = 0.05
NHS2 T/T 140 (46.5) 270 (44.3) 1.00 (reference)
T/C 131 (43.5) 259 (42.5) 0.97 (0.72–1.31)
C/C 30 (10.0) 81 (13.3) 0.72 (0.45–1.15)
p trend = 0.26
WHS T/T 281 (43.6) 278 (42.7) 1.00 (reference)
T/C 296 (46.0) 294 (45.2) 0.99 (0.78–1.26)
C/C 67 (10.4) 79 (12.1) 0.86 (0.58–1.25)
p trend = 0.53
Pooled T/T 962 (43.8) 1,246 (41.8) 1.00 (reference)
T/C 994 (45.3) 1,361 (45.7) 0.93 (0.82–1.05)
C/C 238 (10.8) 373 (12.5) 0.80 (0.66–0.97)
p trend = 0.02
aUnconditional logistic regression controlled for age, age at first birth and parity, menopausal status at diagnosis, history of benign breast disease, 
and family history of breast cancer. CI, confidence interval; NHS, Nurses' Health Study; OR, odds ratio; PTGS2, prostaglandin endoperoxide 
synthase 2; WHS, Harvard Women's Health Study.Available online http://breast-cancer-research.com/content/9/1/R3
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Discussion
Variant expression or activity of PTGS2 could alter the risk of
breast neoplasia, independently of exposure to aspirin. Pros-
taglandins stimulate cell migration and lead to proliferation and
neovascularization [2]. Byproducts of the peroxidase activity of
PTGS2 are free radicals, which are known mutagens [3-5].
Last, prostaglandin E2 induces aromatase, the main enzyme in
the production of estrogen [19].
Recently Langsenlehner and colleagues published an associ-
ation between the rs5275 SNP and breast cancer risk [20].
They observed a doubling in risk with the C/C genotype of this
SNP in comparison with the T/T genotype. Interestingly, this
polymorphism is not in Hardy–Weinberg equilibrium in either
the case or the control group of the study presented by Lang-
senlehner and colleagues. Although the statistical significance
of an inverse association between rs5275 and breast cancer
risk among Caucasians (all three studies presented are more
than 98% Caucasian in origin) as presented here requires rep-
lication, we can comfortably exclude a modest increase in risk
associated with this genotype.
No in vitro or in vivo information regarding any putative change
in function associated with this polymorphism is available.
Given its location in the 3' UTR, the rs5275 polymorphism is a
likely candidate to influence mRNA half-life, which is controlled
by sequence-specific elements in this region of the mRNA
[21]. It is possible that the rs5275 SNP is not a functional var-
iant but a marker in linkage disequilibrium with variant(s) that
alter breast cancer risk. Although linkage disequilibrium is
strong across the PTGS2 gene, differences in the degree and
extent of linkage disequilibrium between populations may
explain variation in risk estimates from one study to another.
Linkage between the rs5275 SNP and a causal variant would
also explain why the strongest association with breast cancer
risk is seen with this polymorphism and not the others. Exami-
nation of how the PTGS2 enzyme works in the breast, and in
particular neoplastic breast cells, could shed light on its rela-
tion to breast cancer risk.
Conclusion
Although polymorphisms, particularly the rs5275 polymor-
phism in the 3' UTR, of PTGS2 may be associated with a
decrease in breast cancer risk, we provide strong evidence
that it is not associated with an increased risk of breast cancer.
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